An Open-Label, Multicenter, Follow-up Trial to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose Up to a Maximum of 150 mg/day in Subjects Aged 16 years or Older Suffering from Epilepsy

Grants and Contracts Details

Effective start/end date3/26/083/25/11


  • UCB Pharma (domestic): $41,746.00